Am. J. Respir. Crit. Care Med., Volume 162, Number 1, July 2000, 154-160

Antimicrobial Treatment Failures in Patients with Community-acquired Pneumonia
Causes and Prognostic Implications

FRANCISCO ARANCIBIA, SANTIAGO EWIG, JOSE ANTONIO MARTINEZ, MAURICIO RUIZ, TORSTEN BAUER, MARIA ANGELES MARCOS, JOSEP MENSA, and ANTONI TORRES

Servei de Pneumologia i Al.lergia Respiratoria, Servei de Malalties Infeccioces, Servei de Microbiologia, Hospital Clinic i Provincial, Universitat de Barcelona, Spain

The aim of the study was to determine the causes and prognostic implications of antimicrobial treatment failures in patients with nonresponding and progressive life-threatening, community-acquired pneumonia. Forty-nine patients hospitalized with a presumptive diagnosis of community-acquired pneumonia during a 16-mo period, failure to respond to antimicrobial treatment, and documented repeated microbial investigation  72 h after initiation of in-hospital antimicrobial treatment were recorded. A definite etiology of treatment failure could be established in 32 of 49 (65%) patients, and nine additional patients (18%) had a probable etiology. Treatment failures were mainly infectious in origin and included primary, persistent, and nosocomial infections (n = 10 [19%], 13 [24%], and 11 [20%] of causes, respectively). Definite but not probable persistent infections were mostly due to microbial resistance to the administered initial empiric antimicrobial treatment. Nosocomial infections were particularly frequent in patients with progressive pneumonia. Definite persistent infections and nosocomial infections had the highest associated mortality rates (75 and 88%, respectively). Nosocomial pneumonia was the only cause of treatment failure independently associated with death in multivariate analysis (RR, 16.7; 95% CI, 1.4 to 194.9; p = 0.03). We conclude that the detection of microbial resistance and the diagnosis of nosocomial pneumonia are the two major challenges in hospitalized patients with community-acquired pneumonia who do not respond to initial antimicrobial treatment. In order to establish these potentially life-threatening etiologies, a regular microbial reinvestigation seems mandatory for all patients presenting with antimicrobial treatment failures.

This article has been cited by other articles:

				S. Aliberti, A. Amir, P. Peyrani, M. Mirsaeidi, M. Allen, B. K. Moffett, J. Myers, F. Shaib, M. Cirino, J. Bordon, et al. Incidence, Etiology, Timing, and Risk Factors for Clinical Failure in Hospitalized Patients With Community-Acquired Pneumonia Chest, November 1, 2008; 134(5): 955 - 962. [Abstract] [Full Text] [PDF]

				H. Kothe, T. Bauer, R. Marre, N. Suttorp, T. Welte, K. Dalhoff, and the Competence Network for Community-Acquired Pneu Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment Eur. Respir. J., July 1, 2008; 32(1): 139 - 146. [Abstract] [Full Text] [PDF]

				S. Reyes, R. Martinez, J. M. Valles, E. Cases, and R. Menendez Determinants of hospital costs in community-acquired pneumonia Eur. Respir. J., May 1, 2008; 31(5): 1061 - 1067. [Abstract] [Full Text] [PDF]

				C. Asche, C. McAdam-Marx, B. Seal, B. Crookston, and C. D. Mullins Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance J. Antimicrob. Chemother., May 1, 2008; 61(5): 1162 - 1168. [Abstract] [Full Text] [PDF]

				R Menendez, M Cavalcanti, S Reyes, J Mensa, R Martinez, M A Marcos, X Filella, M Niederman, and A Torres Markers of treatment failure in hospitalised community acquired pneumonia Thorax, May 1, 2008; 63(5): 447 - 452. [Abstract] [Full Text] [PDF]

				R. Menendez and A. Torres Treatment Failure in Community-Acquired Pneumonia Chest, October 1, 2007; 132(4): 1348 - 1355. [Abstract] [Full Text] [PDF]

				M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Leven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, and T. J. M. Verheij Guidelines for the management of adult lower respiratory tract infections Eur. Respir. J., December 1, 2005; 26(6): 1138 - 1180. [Abstract] [Full Text] [PDF]

				R Menendez, A Torres, R Zalacain, J Aspa, J J Martin Villasclaras, L Borderias, J M Benitez Moya, J Ruiz-Manzano, F Rodriguez de Castro, J Blanquer, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome Thorax, November 1, 2004; 59(11): 960 - 965. [Abstract] [Full Text] [PDF]

				B. Roson, J. Carratala, N. Fernandez-Sabe, F. Tubau, F. Manresa, and F. Gudiol Causes and Factors Associated With Early Failure in Hospitalized Patients With Community-Acquired Pneumonia Arch Intern Med, March 8, 2004; 164(5): 502 - 508. [Abstract] [Full Text] [PDF]

				A. A. El-Solh, A. T. Aquilina, R. S. Dhillon, F. Ramadan, P. Nowak, and J. Davies Impact of Invasive Strategy on Management of Antimicrobial Treatment Failure in Institutionalized Older People with Severe Pneumonia Am. J. Respir. Crit. Care Med., October 15, 2002; 166(8): 1038 - 1043. [Abstract] [Full Text] [PDF]

				D. C. Angus, T. J. Marrie, D. S. Obrosky, G. Clermont, T. T. Dremsizov, C. Coley, M. J. Fine, D. E. Singer, and W. N. Kapoor Severe Community-acquired Pneumonia: Use of Intensive Care Services and Evaluation of American and British Thoracic Society Diagnostic Criteria Am. J. Respir. Crit. Care Med., September 1, 2002; 166(5): 717 - 723. [Abstract] [Full Text] [PDF]

				A. Ortqvist Treatment of community-acquired lower respiratory tract infections in adults Eur. Respir. J., July 1, 2002; 20(36_suppl): 40S - 53s. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788. [Full Text] [PDF]

				R. G. Wunderink and G. W. Waterer Appropriate Microbiological Testing in Community-Acquired Pneumonia Chest, January 1, 2001; 119(1): 5 - 7. [Full Text] [PDF]